摘要
目的探讨瑞格列奈联合吡格列酮治疗2型糖尿病的临床效果。方法选择本院2010年2月～2012年12月收治的80例2型糖尿病患者为研究对象,根据治疗方法将80例患者分为对照组与观察组,每组各40例,对照组给予瑞格列奈治疗,观察组给予在对照组的基础上给予吡格列酮治疗,观察两组的FPG、2hPG、HbA1C、LDL-C及TG。结果两组患者治疗后各项指标均降低,对照组治疗后FPG、2hPG、HbA1C、LDL-C以及TG与治疗前比较,差异无统计学意义(P>0.05)。观察组治疗后FPG、2hPG、HbA1C和LDL-C与治疗前比较,差异有统计学意义(P<0.05),而治疗前后TG比较,差异无统计学意义(P>0.05)。结论瑞格列奈联合吡格列酮治疗2型糖尿病效果优于单独用药。
Objective To explore the clinical effect of repaglinide combine with pioglitazone theratment of type 2 diabetes. Methods 80 patients with type 2 diabetes in our hospital from February 2010 to December 2012 were elected as the research objective, 80 patients were divided into control group and observation group according to the treatment methods, 40 cases in each group. The control group patients were given repaglinide treated. The observation group patients were given pioglitazone treated on the basis of the control group, the FPG, 2 h PG, HbAle, LDL-C and TG between the two groups were observed. Results The every index was reduced after treatment in both groups, the FPG, 2 h PG, HbA1C, TG, LDL-C in control group after treatment compared with before treatment, there was no statistically significant difference （P 〉 0.05）. The FPG, 2 h PG, HbA1C, and LDL-C after treatment in observation group compared with before treatment, the difference was statistically significant （P 〈 0.05）, but the TG compared before and after the treatment, there was no statistically significant difference （P 〉 0.05）. Conclusion Repaglinide combine with pioglitazone therapy in type 2 diabetes is better than alone.
出处
《中国医药科学》
2013年第12期77-78,共2页
China Medicine And Pharmacy
